MBX Biosciences Inc. has published a presentation outlining key upcoming milestones across its pipeline of precision peptide therapies for endocrine and metabolic diseases. The company plans to initiate a Phase 3 trial for canvuparatide, its investigational once-weekly parathyroid hormone replacement therapy for hypoparathyroidism, in the third quarter of 2026. Results from a one-year open-label extension and additional Phase 2 data are expected in the second quarter of 2026. Other programs include MBX 4291, a GLP-1/GIP candidate with 12-week multiple ascending dose results anticipated in the fourth quarter of 2026, and two additional candidates, MBX 5XXX and MBX 6XXX, with development nominations planned for 2026. The company reports $373.7 million in cash as of December 31, 2025, providing runway into 2029. You can access the full presentation through the link below.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. MBX Biosciences Inc. published the original content used to generate this news brief on January 13, 2026, and is solely responsible for the information contained therein.